Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.51 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.51 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.51 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | P2RX6 | O15547 | 1/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.45 |
| ▸ | P2RX5 | Q93086 | 1/20 | 0.45 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 2/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5694235 | 0.90 | NT5E (0.46) | P2RX3P2RX4P2RX2P2RX1P2RY11 | |
| SCHEMBL5908146 | 0.86 | P2RX3 (0.45) | P2RX3P2RX4P2RX2ENPP1ABCB1 | |
| SCHEMBL5908145 | 0.84 | ST6GAL1 (0.39) | NT5EP2RY12 | |
| SCHEMBL20777996 | 0.83 | P2RY12 (0.44) | P2RY12 | |
| SCHEMBL20908639 | 0.83 | P2RY12 (0.44) | P2RY12 | |
| SCHEMBL23621360 | 0.83 | P2RY12 (0.44) | P2RY12 | |
| SCHEMBL30292626 | 0.83 | P2RY12 (0.44) | P2RY12 | |
| SCHEMBL20908488 | 0.83 | P2RY12 (0.44) | P2RY12 | |
| SCHEMBL23621322 | 0.83 | P2RY12 (0.44) | P2RY12 | |
| SCHEMBL26291929 | 0.83 | P2RY12 (0.44) | P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1645561-A1 | METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2006-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | P2RX3 4092/4885P2RX4 4376/4885P2RX2 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.